Title of Invention	SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOFAND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES
Abstract	The invention relates to new imidazolidine-type compounds of formula (I) in which Rl to R7 have the meanings disclosed in the claims. Said compounds represent potent inhibitors of sodiumlhydrogen exchanger (NHE), particularly NHE. These novel compounds are used to produce a drug for the therapy or prophylaxis of the central nervous system, lipometabolism, infestations by ectoparasites, dysfunctions of the gall and for improving respiratory drive. The inventive compounds are therefore used for the therapy of respiratory conditions in the following clinical states and diseases: malfunctioning central respiratory drive (e.g. sleep apnoea, sudden infant death, postoperative hypoxia), muscle- related breathing disturbances, breathing disturbances following long-term respiration, breathing disturbances when adapting to high mountain areas, obstructive sleep apnoea and a mixed type of sleep apnoea, acute and chronic lung diseases with hypoxia and hypercapnia. Said compounds also increase the muscle tone in the upper respiratory tract so as to suppress snoring.

Title of Invention

SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOFAND DRUG CONTAINING SUBSTITUTED IMIDAZOLIDINES

Abstract

The invention relates to new imidazolidine-type compounds of formula (I) in which Rl to R7 have the meanings disclosed in the claims. Said compounds represent potent inhibitors of sodiumlhydrogen exchanger (NHE), particularly NHE. These novel compounds are used to produce a drug for the therapy or prophylaxis of the central nervous system, lipometabolism, infestations by ectoparasites, dysfunctions of the gall and for improving respiratory drive. The inventive compounds are therefore used for the therapy of respiratory conditions in the following clinical states and diseases: malfunctioning central respiratory drive (e.g. sleep apnoea, sudden infant death, postoperative hypoxia), muscle- related breathing disturbances, breathing disturbances following long-term respiration, breathing disturbances when adapting to high mountain areas, obstructive sleep apnoea and a mixed type of sleep apnoea, acute and chronic lung diseases with hypoxia and hypercapnia. Said compounds also increase the muscle tone in the upper respiratory tract so as to suppress snoring.

Full Text

Documents:

1399-chenp-2004 abstract.pdf

1399-chenp-2004 claims granted.pdf

1399-chenp-2004 correspondence others.pdf

1399-chenp-2004 correspondence po.pdf

1399-chenp-2004 description (complete) granted.pdf

1399-chenp-2004 form 1.pdf

1399-chenp-2004 form 13.pdf

1399-chenp-2004 form 3.pdf

1399-chenp-2004 form 5.pdf

1399-chenp-2004 pct.pdf

1399-chenp-2004 petition.pdf

1399-chenp-2004 power of attorney.pdf

« Previous Patent

Next Patent »

Patent Number

224428

Indian Patent Application Number

1399/CHENP/2004

PG Journal Number

49/2008

Publication Date

05-Dec-2008

Grant Date

15-Oct-2008

Date of Filing

21-Jun-2004

Name of Patentee

SANOFI-AVENTIS DEUTSCHLAND GMBH

Applicant Address

BRUNINGGSTRASSE 50, D-65929 FRANKFURT AM MAIN,

Inventors:

#	Inventor's Name	Inventor's Address
1	HEINELT, UWE	MOSBACHER STRASSE 54, 65187 WIESBADEN,
2	LANG, HANS--JOCHEN	RUDESHEIMER STRASSE 7, 65719 HOFHEIM,
3	HOFMEISTER, ARMIN	PFAUGASS 16, 55276 OPPENHEIM,
4	WIRTH, KLAUS	ROBERT-SCHUMANN-RING 104, 65830 KRIFTEL,

PCT International Classification Number

A61K31/4168

PCT International Application Number

PCT/EP02/13921

PCT International Filing date

2002-12-09

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	101 63 239.8	2001-12-21	Germany